| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2018-01-02 | tabelecleucel (formerly known as ATA129) | rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD) | 3 | Atara Biotherapeutics (USA - CA) | Cancer - Oncology |
| 2018-01-02 | tislelizumab (BGB-A317) | hepatocellular carcinoma | 3 | BeiGene (China) | Cancer - Oncology |
| 2017-12-29 | HyLeukin® | advanced solid tumors | 1b | Genexine (Republic of Korea) | Cancer - Oncology |
| 2017-12-27 | Iomab-B (131I apamistamab) | acute myeloid leukemia (AML) | 3 | Actinium Pharmaceuticals (USA - NJ) | Cancer - Oncology |
| 2017-12-27 | imeglimin | type 2 diabetes | 3 | Poxel (France) Sumitomo Dainippon Pharma (Japan) | Metabolic diseases |
| 2017-12-27 | locally advanced cutaneous melanoma | Provectus Pharmaceuticals (USA - TN) | Cancer - Oncology | ||
| 2017-12-27 | VB-111 (ofranergene obadenovec) | platinum-resistant ovarian cancer | 3 | VBL Therapeutics (Israel) | Cancer - Oncology |
| 2017-12-27 | eteplirsen | Duchenne Muscular Dystrophy | 2b | Sarepta Therapeutics (USA - MA) | Genetic diseases - Neuromuscular diseases - Rare diseases |
| 2017-12-26 | AG-270 | tumor types carrying an MTAP deletion | 1 | Peregrine Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2017-12-22 | Yeliva™ (ABC294640) | cholangiocarcinoma | 2a | Redhill Biopharma (Israel) | Cancer - Oncology |
| 2017-12-22 | anabasum (JBT-101 ) | systemic lupus erythematosus (SLE) | 2 | Corbus Pharmaceuticals (USA - MA) | Autoimmune diseases |
| 2017-12-22 | SCB-808 (biosimilar etanercept) | rheumatoid arthritis and other autoimmune diseases | 1 | Clover Biopharmaceuticals (China) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2017-12-21 | caplacizumab | acquired thrombotic thrombocytopenic purpura (TTP) | 1 | Ablynx (Belgium) | Autoimmune diseases - Rare diseases |
| 2017-12-21 | SNF472 - hexasodium phytate | calciphylaxis | Sanifit (Spain - Switzerland) | Rare diseases - Cardiovascular diseases | |
| 2017-12-21 | gemcabene | NASH (non-alcoholic steatohepatitis)/nonalcoholic fatty liver disease (NAFLD) - Familial Partial Lipodystrophy (FPL) | 2a | Gemphire Therapeutics (USA - Mich) | Liver diseases - Hepatic diseases |
| 2017-12-21 | Revlimid® (lenalidomide) and rituximab | previously untreated follicular lymphoma | 3 | Celgene (USA - NJ) Lysarc (France) | Cancer - Oncology |
| 2017-12-21 | PCM-075 (1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt) | acute myeloid leukemia (AML) | 1b-2 | Trovagene (USA - CA) | Cancer - Oncology |
| 2017-12-21 | SAB-136 | antibiotic-resistant bacteria. Mycoplasma hominis | 1 | SAB Biotherapeutics (USA - SD) | Infectious diseases |
| 2017-12-21 | BAN2401 | Alzheimer's disease | 2 | Eisai (Japan) Biogen (USA - MA) | Neurodegenerative diseases |
| 2017-12-20 | JHL1149 (biosimilar version of bevacizumab - Avastin®) | 1 | JHL Biotech (Taiwan) | Cancer - Oncology |
